The Childhood Cancer Blog

Just Funded: 24 New Pediatric Oncology Research Projects

Home » Blog

By: Trish Adkins

What does it take to cure childhood cancer? For the 24 new Alex’s Lemonade Stand Foundation Young Investigator grantees, the answer lies in pursuing innovative approaches to the pressing questions that could unlock new possibilities for kids with cancer.

This year, Alex’s Lemonade Stand Foundation (ALSF) is supporting these early-career researchers as they pursue bold ideas that could lead to new ways of understanding, diagnosing, and treating childhood cancer. Through the 2026 Young Investigator Grants, ALSF is investing in scientists at a pivotal stage in their careers—when a promising idea can become an independent research program and, ultimately, a discovery that changes what’s possible for children with cancer.

This year’s newly funded projects bring fresh perspectives and unconventional approaches to childhood cancer research. They address treatment inequities, harness emerging technologies, investigate serious treatment-related side effects, and tackle some of the deadliest childhood cancers.

“Receiving this award feels like a green light to pursue an unconventional approach to childhood cancer,” said Dr. Rosa Vincent, an ALSF grantee who is engineering helpful bacteria to live inside solid tumors and provide more fuel to engineered T cells so they can fight cancer cells.

“Having my work recognized and supported by ALSF has helped pull my research out of the abstract world of cells in a dish and toward the children and families we ultimately hope it will benefit,” said Dr. Vincent.

For early-career scientists, Young Investigator Grant funding provides something just as valuable as research dollars: protected time to expand their work, test new ideas, and build independent research programs.

Dr. Alexis Boulter is using her funding to investigate how a warming climate could influence treatment-related complications in children with leukemia.

“Because exposure to extreme heat is shaped by longstanding inequities in housing, urban planning, and environmental policy, this research seeks to understand how these factors contribute to treatment-related complications and disparities in outcomes,” explained Dr. Boulter.

Dr. Julie Boiko is studying graft-versus-host disease (GVHD), a serious and sometimes deadly complication of stem cell transplants. She is using her funding to take a genomic deep dive into the biology of GVHD, with the goal of better understanding what causes its most severe forms.

“I am excited to get to uncover the causes of morbid forms of graft-versus-host disease and learn how we can more efficiently and effectively treat it,” said Dr. Boiko.

Brain tumors are the deadliest form of childhood cancer, and many critical questions about these cancers remain unanswered.

Dr. Tristen Wright is pursuing one of those questions in ependymoma, a type of pediatric brain tumor. He will study how the major drivers of ependymoma development work and whether this new understanding could reveal vulnerabilities that might ultimately become targets for more effective treatments.

“The ALSF Young Investigator Grant represents far more than research funding—it provides the opportunity to launch my independent laboratory and dedicate my career to developing better treatments for children with brain tumors. Knowing that this work is made possible by the generosity of ALSF supporters is both motivating and humbling, and I am grateful for the opportunity to help improve the lives of children and families affected by pediatric cancer,” said Dr. Wright.

Another funded researcher, Dr. Julia Carrillo-García, is examining how external stress on the developing brain—including injury or increased pressure inside the skull—can alter the behavior of cells and contribute to tumor development.

“Receiving this grant is incredibly meaningful to me, both scientifically and at this stage of my career. It gives me the opportunity to explore ideas that I hope will help us better understand previously overlooked factors that may contribute to childhood brain tumors,” said Dr. Carrillo-García.

ALSF Young Investigators gain more-than-valuable funding for their research. They also become part of a robust research community through ALSF. Each year, Young Investigator grantees and alumni come together to discuss their projects, collaborate, and problem-solve—continuing to connect around some of the most pressing challenges in childhood cancer research.

Funding childhood cancer research has never been more important. Breakthroughs often emerge from bold, unconventional approaches, but those ideas need funding to become discoveries.

By supporting early-career investigators, ALSF helps spark creativity, bring fresh perspectives to the field, and give the next generation of researchers the opportunity to pursue the urgent goal at the heart of all this work: curing childhood cancer.

Below, meet the newest group of Young Investigator Grantees and explore the innovative projects they’re launching.

Researcher Cancer Type Project
Rosa Vincent, PhD Neuroblastoma, osteosarcoma Engineering therapeutic probiotics to enhance GD2-CAR T cell efficacy in pediatric solid tumors
Tristen Wright, PhD Ependymoma Decoding fusion oncoprotein-driven protein interaction landscapes to reveal therapeutic vulnerabilities in pediatric ependymoma
Monica Pomaville, MD DIPG, glioma Nucleic acid-based strategy targeting fusion oncogenes in CNS tumors
Mohammad Ali Mohammad Nezhady, PhD Neuroblastoma Leveraging oncogenic mutant-ATRX driven collateral vulnerabilities to identify novel therapeutic approaches
Jhullian Alston, PhD Rhabdomyosarcoma Engineering peptides that target disordered regions in PAX3-FOXO1-positive alveolar rhabdomyosarcoma
Julie Boiko, MD/PhD Leukemia, lymphoma Tissue macrophage fibrogenesis in chronic graft-versus-host disease following hematopoietic cell transplantation 
Alexis Boulter, MD Acute lymphoblastic leukemia (ALL) The influence of extreme heat on renal toxicities in pediatric leukemia patients
Alberto Bueno-Costa, PhD Ewing sarcoma Uncovering the intrinsic mechanisms of B7-H3 upregulation in Ewing sarcoma to enable next-generation CAR T cell therapy
Julia Carrillo-García, PhD Medulloblastoma Brain compression as an early driver of malignancy in pediatric medulloblastoma
Matthew Decker, MD/PhD Acute myeloid leukemia (AML) The NRAS palmitoylation cycle as a therapeutic target in pediatric leukemia
Lara Engertsberger, MD Glioblastoma, DIPG Co-targeting gangliosides to overcome antigen heterogeneity in H3-wildtype pediatric high-grade glioma
Jodi Forward, MD Acute lymphoblastic leukemia (ALL) Targeting Beta-catenin Nuclear Export and Protein Degradation in High-Risk Acute Lymphoblastic Leukemia
Margery Gang, MD Acute myeloid leukemia (AML) Optimizing CD33-Targeted Antibody-Drug Conjugate Therapy for Acute Myeloid Leukemia
Alberto Guerra, MD/PhD Neuroblastoma Characterizing determinants of response and therapeutic barriers to novel antibody-drug conjugates (ADCs) targeting the Anaplastic Lymphoma Kinase (ALK) oncoprotein in neuroblastoma
Jihee Lee, PhD Rhabdomyosarcoma Cell state plasticity is required for metastatic tumor growth in FN-RMS
Robert Lindquist, MD/PhD Ependymoma Discovering therapeutic targets in human iPSC-derived models of ZFTA::RELA ependymoma
Mingjun Liu, PhD Acute myeloid leukemia (AML) Mechanisms and therapeutic targets of UBTF tandem duplication in pediatric acute myeloid leukemia
Borja Ruiz, PhD Osteosarcoma ENPP1 as a therapeutic strategy for osteosarcoma
Alba Sommerschield, MD Acute myeloid leukemia (AML) Targeting KAT2A-Dependent Oncogenic Transcriptional Programs in Pediatric AML Using a Novel Molecular Glue Degrader
Edward Song, PhD DIPG, spinal cord tumor Enhancing CAR T Cell Therapy for Diffuse Intrinsic Pontine Glioma by Promoting CAR T Cell Persistence with Novel Manufacturing Approach and Immune Checkpoint Receptor Modifications
Patricia Sullivan, PhD Brain tumor Decoding splicing dysregulation in pediatric CNS tumors through multi-omic integration
Ke Wang, PhD Acute myeloid leukemia (AML) Targeting WT1-Mutant Stem-like Programs Driving Lineage Plasticity and Therapy Resistance in Pediatric AML
Katelyn Williams, MD/PhD Ewing sarcoma Defining immune landscapes and IL-1RAP driven myeloid immunosuppression in Ewing sarcoma
Wanki Yoo, PhD Acute myeloid leukemia (AML), chronic myeloid leukemia (CML) Structural and Functional Dissection of PR-DUB Dysregulation by ASXL1 Truncations in pediatric acute myeloid leukemia (AML)